CHO PHARMA is a Taiwan-based biotechnology company founded in 2013 by a team of distinguished glycoscience leaders. Rooted in glycoscience, we are committed to translating the cutting-edge science into best-in-class medicines for people suffering from limited or inadequate treatment options.
CHO PHARMA is equipped with advanced carbohydrate-based vaccine technology to develop a bivalent vaccine that targets two major Klebsiella pneumonia (KP) pathogenic serotypes K1 and K2. Preclinical studies have proven that CHO-V08 vaccine can induce potent antibody response against the hypervirulent KP strains. FDA approved CHO-V08 to conduct phase I clinical trial.